Billionaire Ken Fisher’s Top 10 High Growth Stock Picks

6. Novo Nordisk A/S (NYSE:NVO)

Net revenue growth in the past 12 months: 26.15%

Novo Nordisk A/S (NYSE:NVO), a global leader in healthcare specializing in treatments for chronic diseases like diabetes, obesity, hemophilia, and growth disorders, has recently faced market volatility. The company’s stock declined approximately 20% following clinical trial results for its obesity drug, CagriSema. The trial showed a weight reduction of 22.7%, slightly below the expected 25%, which caused investor concerns. Despite this temporary setback, the company remains well-positioned in its market.

In January 2025, Novo Nordisk (NYSE:NVO) expanded its partnership with Valo Health. This collaboration integrates human health data and AI technology to accelerate the development of new treatments for obesity, type 2 diabetes, and heart disease. Novo Nordisk committed $190 million in initial payments, with potential milestone-based payouts totaling up to $4.6 billion. This substantial investment highlights the company’s focus on innovation and addressing unmet needs in chronic disease management.

Analysts maintain a positive outlook on Novo Nordisk’s (NYSE:NVO) prospects. UBS Group recently upgraded its rating on the stock from “Sell” to “Buy,” citing confidence in the company’s strategic initiatives and market leadership. The continued investment in partnerships and product portfolio expansion reinforces the company’s resilience and growth potential.